{"product_id":"new-drugs-and-clinical-trials-rules-2019-with-allied-laws-rajan-nijhawan-ilbco-india","title":"New Drugs and Clinical Trials Rules, 2019 | With Allied Laws | Rajan Nijhawan | ILBCO INDIA","description":"\u003ch1\u003e📘 \u003cstrong\u003eNew Drugs and Clinical Trials Rules, 2019 | With Allied Laws | Rajan Nijhawan | ILBCO INDIA\u003c\/strong\u003e\n\u003c\/h1\u003e\n\u003cp\u003e\u003cem\u003eNew Drugs and Clinical Trials Rules, 2019 | With Allied Laws\u003c\/em\u003e by \u003cstrong\u003eRajan Nijhawan\u003c\/strong\u003e, published by \u003cstrong\u003eILBCO INDIA\u003c\/strong\u003e, is a specialized legal and regulatory reference covering the \u003cstrong\u003eNew Drugs and Clinical Trials Rules, 2019 (NDCT Rules)\u003c\/strong\u003e along with relevant allied laws.\u003c\/p\u003e\n\u003cp\u003eThe book is useful for understanding the regulatory framework governing \u003cstrong\u003enew drug approvals, clinical trials, investigational new drugs, ethics committees, clinical research, bioavailability and bioequivalence studies, import and manufacture of new drugs, compensation and regulatory compliance\u003c\/strong\u003e.\u003c\/p\u003e\n\u003cp\u003eThe \u003cstrong\u003eNew Drugs and Clinical Trials Rules, 2019\u003c\/strong\u003e were notified under the \u003cstrong\u003eDrugs and Cosmetics Act, 1940\u003c\/strong\u003e and provide the regulatory framework for important aspects of new-drug development and clinical research in India. \u003c\/p\u003e\n\u003chr\u003e\n\u003ch1\u003e⭐ \u003cstrong\u003eBook Details\u003c\/strong\u003e\n\u003c\/h1\u003e\n\u003cp\u003e🏢 \u003cstrong\u003ePublisher:\u003c\/strong\u003e ILBCO INDIA\u003c\/p\u003e\n\u003cp\u003e✍️ \u003cstrong\u003eAuthor:\u003c\/strong\u003e \u003cstrong\u003eRajan Nijhawan\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e📖 \u003cstrong\u003eTitle:\u003c\/strong\u003e \u003cstrong\u003eNew Drugs and Clinical Trials Rules, 2019 | With Allied Laws\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e🌐 \u003cstrong\u003eLanguage:\u003c\/strong\u003e English\u003c\/p\u003e\n\u003cp\u003e📖 \u003cstrong\u003eCategory:\u003c\/strong\u003e Drug Laws | Clinical Trials | Pharmaceutical Law | Health Law | Medical Research Law | Regulatory Law\u003c\/p\u003e\n\u003cp\u003e🎯 \u003cstrong\u003eSuitable For:\u003c\/strong\u003e Law Students | Pharmaceutical Professionals | Clinical Research Professionals | Advocates | Legal Researchers | Compliance Professionals | Healthcare Professionals | Regulatory Affairs Professionals\u003c\/p\u003e\n\u003chr\u003e\n\u003ch1\u003e🚀 \u003cstrong\u003eWhy This Book is Important\u003c\/strong\u003e\n\u003c\/h1\u003e\n\u003cp\u003eThe \u003cstrong\u003eNew Drugs and Clinical Trials Rules, 2019\u003c\/strong\u003e establish an important regulatory framework for new drugs and clinical research in India. The Rules are made under the \u003cstrong\u003eDrugs and Cosmetics Act, 1940\u003c\/strong\u003e. \u003c\/p\u003e\n\u003cp\u003eThis book helps readers understand important areas such as:\u003c\/p\u003e\n\u003cp\u003e✔️ New Drug Approval\u003c\/p\u003e\n\u003cp\u003e✔️ Clinical Trials\u003c\/p\u003e\n\u003cp\u003e✔️ Investigational New Drugs\u003c\/p\u003e\n\u003cp\u003e✔️ Ethics Committees\u003c\/p\u003e\n\u003cp\u003e✔️ Bioavailability \u0026amp; Bioequivalence Studies\u003c\/p\u003e\n\u003cp\u003e✔️ Import \u0026amp; Manufacture of New Drugs\u003c\/p\u003e\n\u003cp\u003e✔️ Regulatory Permissions\u003c\/p\u003e\n\u003cp\u003e✔️ Clinical Trial Compliance\u003c\/p\u003e\n\u003cp\u003e✔️ Allied Drug Laws\u003c\/p\u003e\n\u003cp\u003e📌 \u003cstrong\u003eDrug Development → Regulatory Approval → Clinical Trial → Safety → Compliance\u003c\/strong\u003e\u003c\/p\u003e\n\u003chr\u003e\n\u003ch1\u003e💊 \u003cstrong\u003e1. New Drugs and Clinical Trials Rules, 2019\u003c\/strong\u003e\n\u003c\/h1\u003e\n\u003cp\u003eThe NDCT Rules provide the regulatory framework for new drugs and clinical trials in India.\u003c\/p\u003e\n\u003cp\u003eReaders can understand:\u003c\/p\u003e\n\u003cp\u003e✔️ Scope of the Rules\u003c\/p\u003e\n\u003cp\u003e✔️ Definitions\u003c\/p\u003e\n\u003cp\u003e✔️ Applicability\u003c\/p\u003e\n\u003cp\u003e✔️ Regulatory Authorities\u003c\/p\u003e\n\u003cp\u003e✔️ Approval Procedures\u003c\/p\u003e\n\u003cp\u003e✔️ Compliance Requirements\u003c\/p\u003e\n\u003cp\u003e📌 \u003cstrong\u003eRules → Applicability → Approval → Regulation → Compliance\u003c\/strong\u003e\u003c\/p\u003e\n\u003chr\u003e\n\u003ch1\u003e🧪 \u003cstrong\u003e2. New Drug Approval\u003c\/strong\u003e\n\u003c\/h1\u003e\n\u003cp\u003eNew drug development requires regulatory review and approval before specified activities can proceed.\u003c\/p\u003e\n\u003cp\u003eStudents and professionals can study:\u003c\/p\u003e\n\u003cp\u003e✔️ New Drug Applications\u003c\/p\u003e\n\u003cp\u003e✔️ Regulatory Approval\u003c\/p\u003e\n\u003cp\u003e✔️ Safety Requirements\u003c\/p\u003e\n\u003cp\u003e✔️ Efficacy Requirements\u003c\/p\u003e\n\u003cp\u003e✔️ Quality Considerations\u003c\/p\u003e\n\u003cp\u003e✔️ Regulatory Assessment\u003c\/p\u003e\n\u003cp\u003eThe CDSCO's current regulatory framework specifically includes processing applications for \u003cstrong\u003enew drug approval\u003c\/strong\u003e under the NDCT framework. \u003c\/p\u003e\n\u003cp\u003e📌 \u003cstrong\u003eApplication → Evaluation → Safety \u0026amp; Efficacy → Approval\u003c\/strong\u003e\u003c\/p\u003e\n\u003chr\u003e\n\u003ch1\u003e🔬 \u003cstrong\u003e3. Clinical Trials\u003c\/strong\u003e\n\u003c\/h1\u003e\n\u003cp\u003eClinical trials are a major component of the Rules.\u003c\/p\u003e\n\u003cp\u003eReaders can understand:\u003c\/p\u003e\n\u003cp\u003e✔️ Clinical Trial Permission\u003c\/p\u003e\n\u003cp\u003e✔️ Trial Phases\u003c\/p\u003e\n\u003cp\u003e✔️ Regulatory Approval\u003c\/p\u003e\n\u003cp\u003e✔️ Trial Conduct\u003c\/p\u003e\n\u003cp\u003e✔️ Safety Monitoring\u003c\/p\u003e\n\u003cp\u003e✔️ Trial Documentation\u003c\/p\u003e\n\u003cp\u003e✔️ Regulatory Compliance\u003c\/p\u003e\n\u003cp\u003e📌 \u003cstrong\u003eProtocol → Approval → Trial → Monitoring → Reporting\u003c\/strong\u003e\u003c\/p\u003e\n\u003chr\u003e\n\u003ch1\u003e🧬 \u003cstrong\u003e4. Investigational New Drugs\u003c\/strong\u003e\n\u003c\/h1\u003e\n\u003cp\u003eInvestigational New Drugs are an important area of pharmaceutical regulatory law.\u003c\/p\u003e\n\u003cp\u003eThe CDSCO's Investigational New Drug division handles applications relating to clinical trials and import or manufacture of investigational new drugs under the NDCT Rules. \u003c\/p\u003e\n\u003cp\u003eImportant areas include:\u003c\/p\u003e\n\u003cp\u003e✔️ Investigational New Drug\u003c\/p\u003e\n\u003cp\u003e✔️ Clinical Trial Application\u003c\/p\u003e\n\u003cp\u003e✔️ Regulatory Permission\u003c\/p\u003e\n\u003cp\u003e✔️ Safety Assessment\u003c\/p\u003e\n\u003cp\u003e✔️ Drug Development\u003c\/p\u003e\n\u003cp\u003e📌 \u003cstrong\u003eInvestigational Drug → Application → Regulatory Review → Clinical Trial\u003c\/strong\u003e\u003c\/p\u003e\n\u003chr\u003e\n\u003ch1\u003e🧪 \u003cstrong\u003e5. Bioavailability \u0026amp; Bioequivalence Studies\u003c\/strong\u003e\n\u003c\/h1\u003e\n\u003cp\u003eBioavailability and bioequivalence studies form part of the regulatory framework covered by the NDCT Rules.\u003c\/p\u003e\n\u003cp\u003eStudents can understand:\u003c\/p\u003e\n\u003cp\u003e✔️ Bioavailability Studies\u003c\/p\u003e\n\u003cp\u003e✔️ Bioequivalence Studies\u003c\/p\u003e\n\u003cp\u003e✔️ Study Approval\u003c\/p\u003e\n\u003cp\u003e✔️ Regulatory Requirements\u003c\/p\u003e\n\u003cp\u003e✔️ Compliance\u003c\/p\u003e\n\u003cp\u003e📌 \u003cstrong\u003eDrug Product → Study → Evaluation → Regulatory Assessment\u003c\/strong\u003e\u003c\/p\u003e\n\u003chr\u003e\n\u003ch1\u003e🏛️ \u003cstrong\u003e6. Ethics Committee\u003c\/strong\u003e\n\u003c\/h1\u003e\n\u003cp\u003eEthics Committees play an important role in protecting the rights, safety and well-being of participants involved in clinical research.\u003c\/p\u003e\n\u003cp\u003eThe CDSCO maintains specific regulatory material concerning \u003cstrong\u003eEthics Committees for clinical trials and bioavailability\/bioequivalence studies\u003c\/strong\u003e under the NDCT framework. \u003c\/p\u003e\n\u003cp\u003eReaders can study:\u003c\/p\u003e\n\u003cp\u003e✔️ Ethics Committee\u003c\/p\u003e\n\u003cp\u003e✔️ Registration\u003c\/p\u003e\n\u003cp\u003e✔️ Review\u003c\/p\u003e\n\u003cp\u003e✔️ Ethical Oversight\u003c\/p\u003e\n\u003cp\u003e✔️ Clinical Trial Monitoring\u003c\/p\u003e\n\u003cp\u003e✔️ Participant Protection\u003c\/p\u003e\n\u003cp\u003e📌 \u003cstrong\u003eClinical Trial → Ethics Review → Participant Protection → Compliance\u003c\/strong\u003e\u003c\/p\u003e\n\u003chr\u003e\n\u003ch1\u003e👥 \u003cstrong\u003e7. Protection of Clinical Trial Participants\u003c\/strong\u003e\n\u003c\/h1\u003e\n\u003cp\u003eClinical research requires appropriate safeguards for participants.\u003c\/p\u003e\n\u003cp\u003eImportant areas include:\u003c\/p\u003e\n\u003cp\u003e✔️ Participant Safety\u003c\/p\u003e\n\u003cp\u003e✔️ Informed Consent\u003c\/p\u003e\n\u003cp\u003e✔️ Ethical Review\u003c\/p\u003e\n\u003cp\u003e✔️ Adverse Events\u003c\/p\u003e\n\u003cp\u003e✔️ Compensation Framework\u003c\/p\u003e\n\u003cp\u003e✔️ Regulatory Oversight\u003c\/p\u003e\n\u003cp\u003e📌 \u003cstrong\u003eParticipant → Consent → Safety → Monitoring → Protection\u003c\/strong\u003e\u003c\/p\u003e\n\u003chr\u003e\n\u003ch1\u003e⚠️ \u003cstrong\u003e8. Safety Monitoring\u003c\/strong\u003e\n\u003c\/h1\u003e\n\u003cp\u003eSafety monitoring is an important component of clinical research regulation.\u003c\/p\u003e\n\u003cp\u003eProfessionals can understand:\u003c\/p\u003e\n\u003cp\u003e✔️ Adverse Events\u003c\/p\u003e\n\u003cp\u003e✔️ Serious Adverse Events\u003c\/p\u003e\n\u003cp\u003e✔️ Safety Reporting\u003c\/p\u003e\n\u003cp\u003e✔️ Clinical Monitoring\u003c\/p\u003e\n\u003cp\u003e✔️ Regulatory Communication\u003c\/p\u003e\n\u003cp\u003e✔️ Pharmacovigilance-Related Requirements\u003c\/p\u003e\n\u003cp\u003e📌 \u003cstrong\u003eTrial → Adverse Event → Reporting → Assessment → Regulatory Action\u003c\/strong\u003e\u003c\/p\u003e\n\u003chr\u003e\n\u003ch1\u003e📑 \u003cstrong\u003e9. Regulatory Applications \u0026amp; Permissions\u003c\/strong\u003e\n\u003c\/h1\u003e\n\u003cp\u003eThe NDCT framework provides various regulatory pathways and forms for applications connected with clinical trials and new drugs.\u003c\/p\u003e\n\u003cp\u003eReaders can understand:\u003c\/p\u003e\n\u003cp\u003e✔️ Regulatory Applications\u003c\/p\u003e\n\u003cp\u003e✔️ Permission Procedures\u003c\/p\u003e\n\u003cp\u003e✔️ Required Documents\u003c\/p\u003e\n\u003cp\u003e✔️ Forms\u003c\/p\u003e\n\u003cp\u003e✔️ Regulatory Authorities\u003c\/p\u003e\n\u003cp\u003e✔️ Approval Process\u003c\/p\u003e\n\u003cp\u003e📌 \u003cstrong\u003eApplication → Documents → Review → Permission\u003c\/strong\u003e\u003c\/p\u003e\n\u003chr\u003e\n\u003ch1\u003e🏭 \u003cstrong\u003e10. Import \u0026amp; Manufacture of New Drugs\u003c\/strong\u003e\n\u003c\/h1\u003e\n\u003cp\u003eThe regulatory framework also deals with activities relating to the \u003cstrong\u003eimport and manufacture of new drugs\u003c\/strong\u003e.\u003c\/p\u003e\n\u003cp\u003eThe CDSCO identifies processes for applications relating to permission for \u003cstrong\u003eimport or manufacture of new drugs for sale or distribution\u003c\/strong\u003e under the NDCT Rules. \u003c\/p\u003e\n\u003cp\u003eImportant areas include:\u003c\/p\u003e\n\u003cp\u003e✔️ Import Permission\u003c\/p\u003e\n\u003cp\u003e✔️ Manufacturing Permission\u003c\/p\u003e\n\u003cp\u003e✔️ Regulatory Approval\u003c\/p\u003e\n\u003cp\u003e✔️ Quality Requirements\u003c\/p\u003e\n\u003cp\u003e✔️ Compliance\u003c\/p\u003e\n\u003cp\u003e📌 \u003cstrong\u003eApplication → Regulatory Approval → Import\/Manufacture → Compliance\u003c\/strong\u003e\u003c\/p\u003e\n\u003chr\u003e\n\u003ch1\u003e🧪 \u003cstrong\u003e11. Clinical Research Organisation\u003c\/strong\u003e\n\u003c\/h1\u003e\n\u003cp\u003eClinical Research Organisations are an important part of the clinical research ecosystem.\u003c\/p\u003e\n\u003cp\u003eThe CDSCO's NDCT regulatory materials include provisions concerning \u003cstrong\u003eregistration of Clinical Research Organisations (CROs)\u003c\/strong\u003e. \u003c\/p\u003e\n\u003cp\u003eReaders can understand:\u003c\/p\u003e\n\u003cp\u003e✔️ Clinical Research Organisations\u003c\/p\u003e\n\u003cp\u003e✔️ Registration\u003c\/p\u003e\n\u003cp\u003e✔️ Regulatory Requirements\u003c\/p\u003e\n\u003cp\u003e✔️ Clinical Trial Management\u003c\/p\u003e\n\u003cp\u003e✔️ Compliance\u003c\/p\u003e\n\u003cp\u003e📌 \u003cstrong\u003eCRO → Registration → Trial Management → Regulatory Compliance\u003c\/strong\u003e\u003c\/p\u003e\n\u003chr\u003e\n\u003ch1\u003e📜 \u003cstrong\u003e12. Allied Laws\u003c\/strong\u003e\n\u003c\/h1\u003e\n\u003cp\u003eThe book also includes \u003cstrong\u003eallied laws\u003c\/strong\u003e, making it useful as a broader legal reference for pharmaceutical and clinical research regulation.\u003c\/p\u003e\n\u003cp\u003eReaders can connect the NDCT Rules with:\u003c\/p\u003e\n\u003cp\u003e✔️ Drugs \u0026amp; Cosmetics Law\u003c\/p\u003e\n\u003cp\u003e✔️ Pharmaceutical Regulation\u003c\/p\u003e\n\u003cp\u003e✔️ Clinical Research Regulation\u003c\/p\u003e\n\u003cp\u003e✔️ Health Law\u003c\/p\u003e\n\u003cp\u003e✔️ Regulatory Compliance\u003c\/p\u003e\n\u003cp\u003e📌 \u003cstrong\u003ePrimary Rules → Allied Laws → Regulatory Framework → Compliance\u003c\/strong\u003e\u003c\/p\u003e\n\u003chr\u003e\n\u003ch1\u003e⚖️ \u003cstrong\u003e13. Regulatory Authorities\u003c\/strong\u003e\n\u003c\/h1\u003e\n\u003cp\u003eThe implementation of drug and clinical trial regulations involves regulatory authorities and specialised bodies.\u003c\/p\u003e\n\u003cp\u003eStudents can understand:\u003c\/p\u003e\n\u003cp\u003e✔️ Central Licensing Authority\u003c\/p\u003e\n\u003cp\u003e✔️ CDSCO\u003c\/p\u003e\n\u003cp\u003e✔️ Regulatory Review\u003c\/p\u003e\n\u003cp\u003e✔️ Expert Committees\u003c\/p\u003e\n\u003cp\u003e✔️ Ethics Committees\u003c\/p\u003e\n\u003cp\u003e✔️ Regulatory Decision-Making\u003c\/p\u003e\n\u003cp\u003e📌 \u003cstrong\u003eAuthority → Application → Review → Decision → Compliance\u003c\/strong\u003e\u003c\/p\u003e\n\u003chr\u003e\n\u003ch1\u003e🔍 \u003cstrong\u003e14. Regulatory Compliance\u003c\/strong\u003e\n\u003c\/h1\u003e\n\u003cp\u003ePharmaceutical and clinical research organisations need to maintain compliance with applicable regulatory requirements.\u003c\/p\u003e\n\u003cp\u003eThe book can help readers understand:\u003c\/p\u003e\n\u003cp\u003e✔️ Regulatory Obligations\u003c\/p\u003e\n\u003cp\u003e✔️ Documentation\u003c\/p\u003e\n\u003cp\u003e✔️ Approvals\u003c\/p\u003e\n\u003cp\u003e✔️ Reporting\u003c\/p\u003e\n\u003cp\u003e✔️ Monitoring\u003c\/p\u003e\n\u003cp\u003e✔️ Compliance Procedures\u003c\/p\u003e\n\u003cp\u003e📌 \u003cstrong\u003eRegulation → Documentation → Monitoring → Reporting → Compliance\u003c\/strong\u003e\u003c\/p\u003e\n\u003chr\u003e\n\u003ch1\u003e🧠 \u003cstrong\u003e15. Drug Development \u0026amp; Regulatory Framework\u003c\/strong\u003e\n\u003c\/h1\u003e\n\u003cp\u003eThe NDCT Rules can be understood as part of the broader drug-development lifecycle.\u003c\/p\u003e\n\u003cp\u003eA simplified framework is:\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eResearch → New Drug → Clinical Trial → Regulatory Review → Approval → Manufacture\/Import → Monitoring\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThis makes the book useful for readers seeking a structured understanding of \u003cstrong\u003epharmaceutical regulatory law\u003c\/strong\u003e.\u003c\/p\u003e\n\u003chr\u003e\n\u003ch1\u003e📝 \u003cstrong\u003e16. Important Study Areas\u003c\/strong\u003e\n\u003c\/h1\u003e\n\u003cp\u003eStudents and professionals should focus on:\u003c\/p\u003e\n\u003cp\u003e✔️ New Drugs\u003c\/p\u003e\n\u003cp\u003e✔️ Clinical Trials\u003c\/p\u003e\n\u003cp\u003e✔️ Investigational New Drugs\u003c\/p\u003e\n\u003cp\u003e✔️ Ethics Committees\u003c\/p\u003e\n\u003cp\u003e✔️ Bioavailability\u003c\/p\u003e\n\u003cp\u003e✔️ Bioequivalence\u003c\/p\u003e\n\u003cp\u003e✔️ Clinical Trial Permissions\u003c\/p\u003e\n\u003cp\u003e✔️ Import \u0026amp; Manufacture\u003c\/p\u003e\n\u003cp\u003e✔️ Regulatory Applications\u003c\/p\u003e\n\u003cp\u003e✔️ Participant Safety\u003c\/p\u003e\n\u003cp\u003e✔️ Adverse Events\u003c\/p\u003e\n\u003cp\u003e✔️ Allied Laws\u003c\/p\u003e\n\u003cp\u003e📌 \u003cstrong\u003eNew Drug → Trial → Ethics → Safety → Approval → Compliance\u003c\/strong\u003e\u003c\/p\u003e\n\u003chr\u003e\n\u003ch1\u003e🎓 \u003cstrong\u003e17. Useful for Law Students\u003c\/strong\u003e\n\u003c\/h1\u003e\n\u003cp\u003eThis book can be useful for students studying specialised areas of law such as:\u003c\/p\u003e\n\u003cp\u003e⚖️ \u003cstrong\u003eHealth Law\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e💊 \u003cstrong\u003ePharmaceutical Law\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e🧪 \u003cstrong\u003eMedical Research Law\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e📚 \u003cstrong\u003eRegulatory Law\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e🏛️ \u003cstrong\u003eAdministrative Law\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e🎓 \u003cstrong\u003eLLB \/ LLM Courses\u003c\/strong\u003e\u003c\/p\u003e\n\u003chr\u003e\n\u003ch1\u003e👨⚕️ \u003cstrong\u003e18. Useful for Pharmaceutical \u0026amp; Clinical Research Professionals\u003c\/strong\u003e\n\u003c\/h1\u003e\n\u003cp\u003eThe book can also serve as a legal reference for professionals working in:\u003c\/p\u003e\n\u003cp\u003e💊 \u003cstrong\u003ePharmaceutical Companies\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e🧪 \u003cstrong\u003eClinical Research Organisations\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e🔬 \u003cstrong\u003eClinical Research\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e🏢 \u003cstrong\u003eRegulatory Affairs\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e📋 \u003cstrong\u003eCompliance\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e⚕️ \u003cstrong\u003eHealthcare \u0026amp; Drug Regulation\u003c\/strong\u003e\u003c\/p\u003e\n\u003chr\u003e\n\u003ch1\u003e🔥 \u003cstrong\u003e19. Why This Book is Recommended\u003c\/strong\u003e\n\u003c\/h1\u003e\n\u003cp\u003e✔️ \u003cstrong\u003eNew Drugs and Clinical Trials Rules, 2019\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e✔️ Written by \u003cstrong\u003eRajan Nijhawan\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e✔️ Published by \u003cstrong\u003eILBCO INDIA\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e✔️ Includes \u003cstrong\u003eAllied Laws\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e✔️ New Drug Approval\u003c\/p\u003e\n\u003cp\u003e✔️ Clinical Trials\u003c\/p\u003e\n\u003cp\u003e✔️ Investigational New Drugs\u003c\/p\u003e\n\u003cp\u003e✔️ Ethics Committees\u003c\/p\u003e\n\u003cp\u003e✔️ Bioavailability \u0026amp; Bioequivalence\u003c\/p\u003e\n\u003cp\u003e✔️ Regulatory Permissions\u003c\/p\u003e\n\u003cp\u003e✔️ Import \u0026amp; Manufacture\u003c\/p\u003e\n\u003cp\u003e✔️ Clinical Research Regulation\u003c\/p\u003e\n\u003cp\u003e✔️ Pharmaceutical Compliance\u003c\/p\u003e\n\u003chr\u003e\n\u003ch1\u003e🎯 \u003cstrong\u003e20. How to Use This Book Effectively\u003c\/strong\u003e\n\u003c\/h1\u003e\n\u003ch3\u003e📖 Step 1\u003c\/h3\u003e\n\u003cp\u003eUnderstand the \u003cstrong\u003eDrugs and Cosmetics Act, 1940\u003c\/strong\u003e framework.\u003c\/p\u003e\n\u003ch3\u003e💊 Step 2\u003c\/h3\u003e\n\u003cp\u003eStudy the definition and regulatory treatment of \u003cstrong\u003enew drugs\u003c\/strong\u003e.\u003c\/p\u003e\n\u003ch3\u003e🧪 Step 3\u003c\/h3\u003e\n\u003cp\u003eUnderstand the \u003cstrong\u003eclinical trial approval and regulatory process\u003c\/strong\u003e.\u003c\/p\u003e\n\u003ch3\u003e🏛️ Step 4\u003c\/h3\u003e\n\u003cp\u003eStudy the role of \u003cstrong\u003eEthics Committees and regulatory authorities\u003c\/strong\u003e.\u003c\/p\u003e\n\u003ch3\u003e⚠️ Step 5\u003c\/h3\u003e\n\u003cp\u003eFocus on \u003cstrong\u003eparticipant safety, adverse events and reporting requirements\u003c\/strong\u003e.\u003c\/p\u003e\n\u003ch3\u003e📚 Step 6\u003c\/h3\u003e\n\u003cp\u003eUse the \u003cstrong\u003eallied laws\u003c\/strong\u003e section to connect the NDCT Rules with the broader pharmaceutical regulatory framework.\u003c\/p\u003e\n\u003cp\u003e📌 \u003cstrong\u003eAct → Rules → Application → Trial → Ethics → Safety → Approval → Compliance\u003c\/strong\u003e\u003c\/p\u003e\n\u003chr\u003e\n\u003ch1\u003e⭐ \u003cstrong\u003eWhy This Book is Recommended\u003c\/strong\u003e\n\u003c\/h1\u003e\n\u003cp\u003e✔️ \u003cstrong\u003eNew Drugs and Clinical Trials Rules, 2019\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e✔️ \u003cstrong\u003eAuthor: Rajan Nijhawan\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e✔️ \u003cstrong\u003ePublisher: ILBCO INDIA\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e✔️ Includes \u003cstrong\u003eAllied Laws\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e✔️ New Drug Regulation\u003c\/p\u003e\n\u003cp\u003e✔️ Clinical Trial Regulation\u003c\/p\u003e\n\u003cp\u003e✔️ Investigational New Drugs\u003c\/p\u003e\n\u003cp\u003e✔️ Ethics Committee\u003c\/p\u003e\n\u003cp\u003e✔️ Bioavailability \u0026amp; Bioequivalence\u003c\/p\u003e\n\u003cp\u003e✔️ Regulatory Approval\u003c\/p\u003e\n\u003cp\u003e✔️ Import \u0026amp; Manufacture\u003c\/p\u003e\n\u003cp\u003e✔️ Pharmaceutical Law\u003c\/p\u003e\n\u003cp\u003e✔️ Clinical Research Law\u003c\/p\u003e\n\u003cp\u003e✔️ Regulatory Compliance\u003c\/p\u003e\n\u003chr\u003e\n\u003ch1\u003e🎯 \u003cstrong\u003eFinal Verdict\u003c\/strong\u003e\n\u003c\/h1\u003e\n\u003cp\u003e\u003cstrong\u003eNew Drugs and Clinical Trials Rules, 2019 | With Allied Laws\u003c\/strong\u003e by \u003cstrong\u003eRajan Nijhawan\u003c\/strong\u003e, published by \u003cstrong\u003eILBCO INDIA\u003c\/strong\u003e, is a specialised legal reference for understanding India's regulatory framework relating to \u003cstrong\u003enew drugs and clinical trials\u003c\/strong\u003e.\u003c\/p\u003e\n\u003cp\u003eThe NDCT Rules were made under the \u003cstrong\u003eDrugs and Cosmetics Act, 1940\u003c\/strong\u003e and cover important regulatory areas including \u003cstrong\u003enew drug approvals, clinical trials, investigational new drugs, bioavailability and bioequivalence studies, Ethics Committees and related regulatory procedures\u003c\/strong\u003e. \u003c\/p\u003e\n\u003cp\u003eThe book can be useful for \u003cstrong\u003elaw students, pharmaceutical professionals, clinical research professionals, regulatory affairs teams, compliance professionals, advocates and legal researchers\u003c\/strong\u003e who need a focused reference on drug and clinical-trial regulation.\u003c\/p\u003e\n\u003cp\u003e✔️ \u003cstrong\u003eRajan Nijhawan\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e✔️ \u003cstrong\u003eILBCO INDIA\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e✔️ New Drugs and Clinical Trials Rules, 2019\u003c\/p\u003e\n\u003cp\u003e✔️ Allied Laws\u003c\/p\u003e\n\u003cp\u003e✔️ Clinical Trials\u003c\/p\u003e\n\u003cp\u003e✔️ New Drug Approval\u003c\/p\u003e\n\u003cp\u003e✔️ Investigational New Drugs\u003c\/p\u003e\n\u003cp\u003e✔️ Ethics Committees\u003c\/p\u003e\n\u003cp\u003e✔️ Bioavailability \u0026amp; Bioequivalence\u003c\/p\u003e\n\u003cp\u003e✔️ Pharmaceutical Law\u003c\/p\u003e\n\u003cp\u003e✔️ Clinical Research Regulation\u003c\/p\u003e\n\u003cp\u003e✔️ Regulatory Compliance\u003c\/p\u003e\n\u003cp\u003e👉 \u003cstrong\u003eA useful specialised reference for studying India's legal and regulatory framework for new drugs and clinical trials.\u003c\/strong\u003e\u003c\/p\u003e\n\u003chr\u003e\n\u003cp\u003eBuy \u003cstrong\u003eNew Drugs and Clinical Trials Rules, 2019 | With Allied Laws\u003c\/strong\u003e by \u003cstrong\u003eRajan Nijhawan\u003c\/strong\u003e, published by \u003cstrong\u003eILBCO INDIA\u003c\/strong\u003e. Covers \u003cstrong\u003enew drug approval, clinical trials, Ethics Committees, investigational drugs, bioavailability, bioequivalence and allied laws\u003c\/strong\u003e.\u003c\/p\u003e\n\u003chr\u003e\n\u003cp\u003eNew Drugs and Clinical Trials Rules 2019 Book\u003c\/p\u003e\n\u003cp\u003eNew Drugs and Clinical Trials Rules Book\u003c\/p\u003e\n\u003cp\u003eNDCT Rules 2019 Book\u003c\/p\u003e\n\u003cp\u003eNew Drugs Clinical Trials Rules India\u003c\/p\u003e\n\u003cp\u003eRajan Nijhawan NDCT Book\u003c\/p\u003e\n\u003cp\u003eILBCO India Drug Law Book\u003c\/p\u003e\n\u003cp\u003eNew Drug Approval Book India\u003c\/p\u003e\n\u003cp\u003eClinical Trial Law Book India\u003c\/p\u003e\n\u003cp\u003eClinical Trials Rules 2019\u003c\/p\u003e\n\u003cp\u003ePharmaceutical Law Book\u003c\/p\u003e\n\u003cp\u003eDrug Regulatory Law Book India\u003c\/p\u003e\n\u003cp\u003eClinical Research Law Book\u003c\/p\u003e\n\u003cp\u003eEthics Committee Clinical Trial Book\u003c\/p\u003e\n\u003cp\u003eBioavailability Bioequivalence Rules Book\u003c\/p\u003e\n\u003cp\u003eDrugs and Cosmetics Act Allied Laws\u003c\/p\u003e\n\u003chr\u003e\n\u003cp\u003eBest New Drugs and Clinical Trials Rules Book\u003c\/p\u003e\n\u003cp\u003eNDCT Rules 2019 Book India\u003c\/p\u003e\n\u003cp\u003eClinical Trial Regulations India Book\u003c\/p\u003e\n\u003cp\u003eNew Drug Approval Law Book\u003c\/p\u003e\n\u003cp\u003eClinical Trial Law for Law Students\u003c\/p\u003e\n\u003cp\u003ePharmaceutical Regulatory Law Book India\u003c\/p\u003e\n\u003cp\u003eNew Drugs Rules 2019 with Allied Laws\u003c\/p\u003e\n\u003cp\u003eClinical Research Regulatory Book\u003c\/p\u003e\n\u003cp\u003eDrug Laws and Clinical Trials Book\u003c\/p\u003e\n\u003cp\u003eRajan Nijhawan New Drugs Book\u003c\/p\u003e\n\u003chr\u003e\n\u003cp\u003e\u003cstrong\u003eNew Drugs and Clinical Trials Rules, 2019 With Allied Laws by Rajan Nijhawan | ILBCO INDIA\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eBest \u003cstrong\u003eNew Drugs and Clinical Trials Rules book for pharmaceutical law and clinical research professionals\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eNew Drugs and Clinical Trials Rules, 2019 | With Allied Laws\u003c\/strong\u003e, by \u003cstrong\u003eRajan Nijhawan\u003c\/strong\u003e, published by \u003cstrong\u003eILBCO INDIA\u003c\/strong\u003e, provides a focused reference on \u003cstrong\u003enew drug approval, clinical trials, investigational new drugs, Ethics Committees, bioavailability and bioequivalence studies, regulatory permissions, import and manufacture of new drugs and allied pharmaceutical laws\u003c\/strong\u003e, making it useful for \u003cstrong\u003elaw students, advocates, pharmaceutical professionals, clinical research professionals, regulatory affairs teams, compliance professionals and legal researchers\u003c\/strong\u003e.\u003c\/p\u003e","brand":"GenZbookcompany","offers":[{"title":"Default Title","offer_id":44332504055942,"sku":null,"price":1766.0,"currency_code":"INR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0651\/2620\/3526\/files\/WhatsAppImage2026-07-22at13.26.59_0e72334d-516b-4a3e-93f2-8c0bf24ce26e.jpg?v=1788235624","url":"https:\/\/genzbookcompany.com\/products\/new-drugs-and-clinical-trials-rules-2019-with-allied-laws-rajan-nijhawan-ilbco-india","provider":"GenZbookcompany","version":"1.0","type":"link"}